HOME >> MEDICINE >> NEWS
Landmark antidepressant analysis demonstrated significant efficacy of Effexor®/Effexor XR

Philadelphia, PA., May 19, 2003 Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), announced today that a landmark analysis of studies comparing antidepressant treatments demonstrated that significantly more patients achieved remission (virtual elimination) of their depression symptoms, and resolution of both emotional and physical symptoms, when treated with EFFEXOR/EFFEXOR XR (venlafaxine HCl) than with commonly used selective serotonin reuptake inhibitors (SSRIs) or placebo. The analysis was presented in two poster presentations at the American Psychiatric Association's (APA) annual meeting in San Francisco.

The analysis compared EFFEXOR®/EFFEXOR XR to the SSRIs PAXIL® (paroxetine), PROZAC® (fluoxetine), ZOLOFT® (sertraline), LUVOX® (fluvoxamine), and CELEXA (citalopram) and comprised the entire worldwide dataset of Wyeth-sponsored registration and post-marketing, published and unpublished, SSRI-controlled clinical studies of EFFEXOR/EFFEXOR XR to date.

"Given the urgency to treat a patient to remission, these data reinforce EFFEXOR XR as a first-line therapy for depression," says Dr. Eric Hollander, Professor of Psychiatry and Director of Psychopharmacology at Mount Sinai School of Medicine in New York City. "This is important information for physicians as remission is a critical milestone in preventing symptom recurrence and depression relapse."

In one poster it was determined that EFFEXOR/EFFEXOR XR-treated patients had significantly higher remission rates than those treated with the studied SSRIs using standard evaluations including scoring seven or less on the 17-item Hamilton Rating Scale for Depression (HAM-D17) and less than 10 on the Montgomery-Asberg Depression Rating Scale (MADRS).

Specifically, the HAM-D17 evaluation revealed a 41 percent remission rate for EFFEXOR/EFFEXOR XR patients, significantly greater than that of patients receiving an SSRI (35 percent, p<0.001), or a placebo (25 percent,
'"/>

Contact: Douglas Petkus, Wyeth Pharmaceuticals
484-865-5140
Porter Novelli
19-May-2003


Page: 1 2 3 4

Related medicine news :

1. Landmark survey reveals asthma in children remains significantly out of control in the United States
2. Landmark study shows coenzyme Q10 slows progressive decline in Parkinsons disease
3. Landmark XENDOS study shows Xenical prevents or delays the development of type 2 diabetes
4. Landmark study demonstrates potential for nerve regeneration treatment of stroke
5. Landmark study results published in NEJM highlight breakthrough treatment for heart failure
6. Landmark study uncovers reasons behind recurring back injury
7. Landmark clinical trial at 22 medical centers finds implanted heart pumps lengthen and improve lives of terminally ill heart failure patients
8. Landmark dialysis study findings could greatly simplify treatment of kidney disease with peritoneal dialysis
9. Landmark school-based social influences smoking-prevention program found not to work
10. U.S., British scientific societies honor penicillin as International Chemical Landmark
11. CODE-2*: Landmark study on the costs of type 2 diabetes in Europe

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/21/2019)... ... 20, 2019 , ... Board Certified plastic surgeon, Brian S. Glatt, MD, FACS ... Fellow of the American College of Surgeons, is licensed to practice plastic and reconstructive ... the American Society of Plastic Surgery and the American Society for Aesthetic Plastic Surgery, ...
(Date:7/19/2019)... ... July 19, 2019 , ... ... hiring of Megan Clem as Senior Director of Education Strategy. Clem has extensive ... , “Having worked globally with physician experts on comprehensive educational programming, Megan brings ...
(Date:7/18/2019)... ... July 18, 2019 , ... ... officials in Congress about new bills to protect patients from unexpected out-of-network medical ... People from Surprise Medical Bills Act ( H.R. 3502 ), introduced in the ...
(Date:7/18/2019)... ATLANTA (PRWEB) , ... July 18, 2019 , ... LEAD ... for Epilepsy organized by the Epilepsy Foundation of Georgia. The event is scheduled to ... front of Building 4 at Concourse Parkway, right under the King & Queen Buildings. ...
(Date:7/18/2019)... CLEARWATER, Fla. (PRWEB) , ... July 18, 2019 , ... ... most recent scientific studies in order to accurately address concerns brought to him by ... types of dental floss has been brought to his attention by patients in his ...
Breaking Medicine News(10 mins):
(Date:7/21/2019)... ... , ... It’s not hard to see the advantages of being an optimist. ... they’re happier, and even healthier. Optimism can also be infectious. Walk into a room ... There’s more to optimism, however, than the positive mindset and hopeful outlook. A recent ...
(Date:7/19/2019)... ... 2019 , ... Today, Licensed Therapist and Founder/Operator of The Missing Peace Center ... Missing Peace with the opening of their newest facility, The Missing Peace Center for ... , The Missing Peace Center for the Brain exclusively offers Neurofeedback as the ...
(Date:7/18/2019)... PLEASANTON, Calif. (PRWEB) , ... July 18, 2019 ... ... (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced ... a UroLift® Center of Excellence. The designation recognizes that Dr. Lesser has achieved ...
Breaking Medicine Technology:
Cached News: